Diabetic autonomic neuropathy is an under-recognised complication of diabetes and the prediabetic state. A wide range of manifestations can be seen due to involvement of cardiovascular, gastrointestinal, genitourinary, sudomotor and neuroendocrine systems. Cardiac autonomic neuropathy is the most dreaded complication carrying significant mortality and morbidity. Early detection and control of diabetes and other cardiovascular risk factors is the key to treat and prevent progression of autonomic neuropathy. Recently, a new entity of treatment-induced neuropathy (TIND) of diabetes mellitus causing autonomic neuropathy is being increasingly recognised.
TesfayeS, BoultonAJ, DyckPJ. Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care2010; 33: 2285–93.
4.
SpalloneV, ZieglerD, FreemanR. Toronto Consensus Panel on Diabetic Neuropathy. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev2011; 27: 639–53.
5.
BernardiL, SpalloneV, StevensM. Toronto Consensus Panel on Diabetic Neuropathy. Methods of investigation for cardiac autonomic dysfunction in human research studies. Diabetes Metab Res Rev2011; 27: 654–64.
6.
FeldmannEL, NaveKA, JenettTS. New Horizons in diabetic neuropathy: mechanisms, bioenergetics and pain. Neuron2017; 93: 1296–313.
7.
CallaghanBC, GallagherG, FridmanV. Diabetic Neuropathy: what does the future hold?Diabetalogia2020; 63: 891–97.
8.
BraffetBH, Gubitosi-KlugRA, AlbersJW. Risk factors for Diabetic Peripheral Neuropathy and Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes2020; 69: 1000–10.
9.
SpalloneV. Update on the Impact, Diagnosis and Management of Cardiovascular Autonomic Neuropathy in Diabetes: What Is Defined, What Is New, and What Is Unmet. Diabetes Metab J2019; 43: 3–30.
10.
YangHeng, SloanG, YeYingchun. New Perpective in Diabetic Neuropathy: From the Periphery to the Brain, a Call for Early Detection, and Precision Medicine Front Endocrinol (Lausanne)2019, 10:929.
11.
HerderC, SchamarekI, NowotnyB. German Diabetes Study Group. Inflammatory markers are associated with cardiac autonomic dysfunction in recent-onset type 2 diabetes. Heart2017; 103: 63-74
12.
CiccacciC, MorgantiR, Di FuscoD. Common polymorphisms in MIR146a, MIR128a and MIR27a genes contribute to neuropathy susceptibility in type 2 diabetes. Acta Diabetol2014; 51: 663–71.
13.
CiccacciC, LatiniA, GrecoC. Association between a MIR499A polymorphism and diabetic neuropathy in type 2 diabetes. J Diabetes Complications2018; 32: 11–17.
14.
HansenCS, JensenJS, RidderstraleM. Vitamin B12 deficiency is associated with cardiovascular autonomic neuropathy in patients with type 2 diabetes. J Diabetes Complications2017; 31: 202–8.
15.
MaserRE, LenhardMJ, PohligRT. Vitamin D insufficiency is associated with reduced parasympathetic nerve fiber function in type 2 diabetes. Endocr Pract2015; 21: 174-81
16.
SlettenDM, SuarezGA, LowPA. COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score. Mayo Clin Proc2012; 87: 1196–201.
17.
Pop-BusuiR, BoultonAJM, FeldmanEL. Diabetic Neuropathy: A Position Statement of American Diabetic Association. Diabetes Care2017; 40: 136–54.
18.
EnglandJD, GronsethGS, FranklinG. American Academy of Neurology. Practice parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology2009; 72: 177–84.
19.
AzmiS, PetropoulosIN, FerdousiM. An update on the diagnosis and treatment of diabetic somatic and autonomic neuropathy. F1000Res. 2019; 8: F1000 Faculty Rev-186. doi:10.12688/f1000research.17118.1
20.
AzmiS, FerdousiM, KaltenieceA. Diagnosing and managing diabetic somatic and autonomic neuropathy. Ther Adv Endocrinol Metab2019; 10: 1–10.
21.
Pop-BusuiR, EvansGW, GersteinHC. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care2010; 33: 1578–84.
22.
AngL, JaiswalM, MartinC. Glucose Control and Diabetic Neuropathy: Lessons from Recent Large Clinical Trials. Curr Diab Rep2014; 14:528.
23.
JordanJ, TankJ, HeusserK. The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus. J Am Soc Hypertens2017; 11: 604–12.
24.
IssacsonS, ShillHA, VerninoS. Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension. J Parkinsons Dis2016; 6:751.
25.
KuznikE, DudkowiakR, AdamiecR. Diabetic autonomic neuropathy of the gastrointestinal tract. Gastroenterol2020; 15: 89–93.
26.
LuoKR, ChaoCC, ChenYT. Quantitation of sudomotor innervation in skin biopsies of patients with diabetic neuropathy. J Neuropathol Exp Neurol2011; 70: 930–38.
27.
GibbonsCH, IlligensBM, WangN. Quantification of sweat gland innervation: a clinical-pathologic correlation. Neurology2009; 72: 1479–86.
